Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with bortezomib could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities.
According to research, more than 80% of MMers who undergo Bortezomib (Velcade) therapy develop chemo-induced peripheral neuropathy. Most of those MMers who have CIPN will experience a reduction in their nerve damage once they discontinue Velcade therapy.
The two central issues of the research linked and excerpted below are 1) therapies (DHA and ALA) to protect the MMer from this painful and often debilitating side effect and 2) the importance of undergoing this preventative therapy as early as possible in order to reduce your chances of reducing or discontinuing bortezomib therapy completely.
The point is that reducing or eliminating bortezomib therapy will negatively impact your therapy plan.
If you or a loved one have been diagnosed with Multiple Myeloma, let me say this loud and clear:
It is critical that you become an active participant in your care. Learn everything you can.
I am alive today largely because I took the time to find out everything I could about Multiple Myeloma and sought out the full spectrum of evidence-based MM therapies both conventional (FDA approved) and non-conventional.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Fortunately, research shows that omega-3 fatty acids (DHA) kill MM as well as enhance MM chemotherapy. I supplement with Life Extension Super Omega 3 as this formula has been evaluated and approved by Consumerlab.com.
According to the study below, the sooner the patient begins to supplement with DHA and ALA the better. There are a host of additional health benefits from DHA and ALA supplementation as well.
Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM patients treated with bortezomib (BTZ), using a new nutritional neuroprotective compound. We report preliminary results of 18 out of 33 patients who completed the study.
Methods: We administered a tablet of Neuronorm to patients, containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for the whole follow-up period. Neurological visit assessment, electroneurography, and evaluation scales were performed at baseline and after 6 months.
Results: At 6 months, 8 patients had no chemotherapy-induced peripheral neuropathy, while 10 patients experienced chemotherapy-induced peripheral neuropathy of grade 1 according to the Common Terminology Criteria for Adverse Events, one of them with pain. Seventeen patients did not report painful symptoms; no limitation of functional autonomy and stability in quality of life domains explored was observed.
Conclusions: Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial.”
“Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. In physiological literature, it is given the name 22:6(n-3). It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk (breast milk), fish oil, or algae oil.“